Supernus Pharmaceuticals (SUPN) Common Equity (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Common Equity data on file, last reported at $1.1 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $1.1 billion, up 4.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 4.47% YoY), and the FY2025 annual result was $1.1 billion, up 2.51% from the prior year.
• Common Equity advanced to $1.1 billion in Q1 2026 per SUPN's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Common Equity peaked at $1.1 billion in Q1 2026 and troughed at $828.4 million in Q1 2022.
• A 5-year average of $958.1 million and a median of $929.2 million in 2024 frame the typical range for Common Equity.
• On a YoY basis, Common Equity climbed as much as 12.39% in 2024 and fell as far as 1.87% in 2024.
• A 5-year view of Common Equity shows it stood at $886.2 million in 2022, then climbed by 3.98% to $921.5 million in 2023, then advanced by 12.39% to $1.0 billion in 2024, then climbed by 2.51% to $1.1 billion in 2025, then advanced by 1.42% to $1.1 billion in 2026.
• Business Quant data shows SUPN's Common Equity at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.